Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 14;40(8):238.
doi: 10.1007/s12032-023-02111-9.

Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment

Harshini Swaminathan  1 , K Saravanamurali  2 , Sangilimuthu Alagar Yadav  3
Affiliations
Review

Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment

Harshini Swaminathan et al. Med Oncol. .

Abstract

As the most frequent and vulnerable malignancy among women, breast cancer universally manifests a formidable healthcare challenge. From a biological and molecular perspective, it is a heterogenous disease and is stratified based on the etiological factors driving breast carcinogenesis. Notably, genetic predispositions and epigenetic impacts often constitute the heterogeneity of this disease. Typically, breast cancer is classified intrinsically into histological subtypes in clinical landscapes. These stratifications empower physicians to tailor precise treatments among the spectrum of breast cancer therapeutics. In this pursuit, numerous prognostic algorithms are extensively characterized, drastically changing how breast cancer is portrayed. Therefore, it is a basic requisite to comprehend the multidisciplinary rationales of breast cancer to assist the evolution of novel therapeutic strategies. This review aims at highlighting the molecular and genetic grounds of cancer additionally with therapeutic and phytotherapeutic context. Substantially, it also renders researchers with an insight into the breast cancer cell lines as a model paradigm for breast cancer research interventions.

Keywords: BRCA1/2; Breast cancer; Chemotherapy; Estrogen receptor; HER2; Mammography.

PubMed Disclaimer

References

    1. De Rose F, Meduri B, Santis MCD, Ferro A, Marino L, Colciago RR, Gregucci F, Vanoni V, Apolone G, Di Cosimo S, Delaloge S, Cortes J, Curigliano G. Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treat Rev. 2022. https://doi.org/10.1016/j.ctrv.2022.102434 . - DOI - PubMed
    1. Ataollahi MR, Sharifi J, Paknahad MR, Paknahad A. Breast cancer and associated factors: a review. J Med Life. 2015;8(4):6–11. - PubMed - PMC
    1. Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, Zeng H, Zhou J, Wei W. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. 2021;41(11):1183–94. https://doi.org/10.1002/cac2.12207 . - DOI
    1. Nel J, Elkhoury K, Velot M, Bianchi A, Acherar S, Francius G, Tamayol A, Grandemange S, Arab-Tehrany E. Functionalized liposomes for targeted breast cancer drug delivery. Bioactive Mater. 2023;24:401–37. https://doi.org/10.1016/j.bioactmat.2022.12.027 . - DOI
    1. He Z, Chen Z, Tan M, Elingarami S, Liu Y, Li T, Deng Y, He N, Li S, Fu J, Li W. A review on methods for diagnosis of breast cancer cells and tissues. Cell Prolif. 2020. https://doi.org/10.1111/cpr.12822 . - DOI - PubMed - PMC

Substances

LinkOut - more resources